Frontline Plc/ CY0200352116 /
30/05/2024 16:43:12 | Chg. -0.77 | Volume | Bid30/05/2024 | Ask30/05/2024 | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
27.96USD | -2.66% | 883,841 Turnover: 21.29 mill. |
27.95Bid Size: 1,300 | 27.96Ask Size: 200 | 6.46 bill.USD | 7.48% | 9.83 |
GlobeNewswire
28/05
Predictive Oncology Announces Positive Results from Ovarian Cancer Study with UPMC Magee-Womens Hosp...
GlobeNewswire
27/05
Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible ...
GlobeNewswire
24/05
Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress
GlobeNewswire
23/05
Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual M...
GlobeNewswire
23/05
Bio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire
21/05
Dalrada Financial Corporation Healthcare Subsidiary, Genefic, Inc., Acquires IV Services Infusion Ph...
GlobeNewswire
20/05
HeartSciences Announces Further Internationalization of its AI-ECG Patent Portfolio
GlobeNewswire
20/05
Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for it...
GlobeNewswire
16/05
Harri Announces Product Innovation Designed to Propel the Frontline Employee Experience and Restaura...
GlobeNewswire
16/05
Dalrada Financial Corporation Files Form 10-Q, Announces Third Quarter Revenue of $10.3 Million
GlobeNewswire
14/05
Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-17215...
GlobeNewswire
14/05
Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML